WhisperX tag archive

#Ophthalmology

This page collects WhisperX intelligence signals tagged #Ophthalmology. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.

Latest Signals (4)

The Lab · 2026-03-26 11:57:08 · Seeking Alpha

1. Kodiak Soars on Phase 3 Success for Diabetic Retinopathy Drug KSI-301

Kodiak Sciences Inc. (KOD) stock surged after the biotech company announced its lead candidate, KSI-301, met its primary endpoint in a pivotal Phase 3 trial for diabetic retinopathy. The positive topline results from the GLEAM study mark a critical inflection point, demonstrating the antibody biopolymer conjugate's pot...

The Vault · 2026-03-31 11:57:19 · STAT News

2. Biogen Acquires Apellis in $5.6 Billion Deal, Doubling Share Price for Immunology Portfolio

Biogen is making a massive $5.6 billion bet on immunology, announcing a deal to acquire Apellis Pharmaceuticals at a price more than double the biotech's recent share value. The upfront cash offer of $41 per share represents a dramatic premium, signaling Biogen's aggressive push to secure commercial-stage assets and re...

The Vault · 2026-03-31 18:57:17 · Seeking Alpha

3. Lensar Projects 46%-49% Gross Margins for 2026, Charts Independent Path After Alcon Deal Collapse

Laser surgical systems maker Lensar is projecting a bold financial target for 2026, forecasting gross margins between 46% and 49%. This forward-looking guidance signals the company's strategic pivot to reignite growth as an independent entity, following the termination of its acquisition deal with industry giant Alcon....

The Lab · 2026-04-08 18:27:20 · STAT News

4. Smart Contact Lens Breakthrough: Early Tests Show Device Can Monitor Eye Pressure & Deliver Glaucoma Drugs

A new smart contact lens has demonstrated the dual capability to continuously monitor intraocular pressure and deliver glaucoma medication on-demand in early-stage testing. This development directly targets the silent, insidious nature of glaucoma—the world's second-leading cause of blindness—where an estimated half of...